Spots Global Cancer Trial Database for mek inhibitor mek162

Every month we try and update this database with for mek inhibitor mek162 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer	NCT02041481	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	MEK inhibitor M... leucovorin calc... fluorouracil oxaliplatin pharmacological... Laboratory Biom...	18 Years -	City of Hope Medical Center
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer	NCT02041481	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	MEK inhibitor M... leucovorin calc... fluorouracil oxaliplatin pharmacological... Laboratory Biom...	18 Years -	City of Hope Medical Center
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer	NCT02041481	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	MEK inhibitor M... leucovorin calc... fluorouracil oxaliplatin pharmacological... Laboratory Biom...	18 Years -	City of Hope Medical Center
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02049801	Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult...	MEK inhibitor M... idarubicin cytarabine pharmacological... laboratory biom...	18 Years - 75 Years	Stanford University
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02049801	Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult...	MEK inhibitor M... idarubicin cytarabine pharmacological... laboratory biom...	18 Years - 75 Years	Stanford University
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02049801	Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult...	MEK inhibitor M... idarubicin cytarabine pharmacological... laboratory biom...	18 Years - 75 Years	Stanford University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: